Additional file 4: of Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial Xiaotong Li Sarah Warren Vasiliki Pelekanou Vikram Wali Alessandra Cesano Mingdong Liu Patrick Danaher Nathane Elliott Zeina Nahleh Daniel Hayes Gabriel Hortobagyi William Barlow Christos Hatzis Lajos Pusztai 10.6084/m9.figshare.7975223.v1 https://springernature.figshare.com/articles/journal_contribution/Additional_file_4_of_Immune_profiling_of_pre-_and_post-treatment_breast_cancer_tissues_from_the_SWOG_S0800_neoadjuvant_trial/7975223 Figure S4. Correlation between TIL counts and PD-L1 expression. A. Correlation between TIL counts and PD-L1 expression on tumor cells. B. Correlation between TIL counts and PD-L1 expression on stromal cells. C. TIL counts in cases with positive and negative PD-L1 expression on tumor cells. D. TIL counts in cases with positive and negative PD-L1 expression on stromal cells. For A and B, Solid line and grey shade represent linear regression line and 95% confidence interval, respectively. Besides, Pearson correlation coefficient r and p-value are added. For C and D, p values are from Wilcoxon test. (PDF 74 kb) 2019-04-10 05:00:00 Tumor infiltrating lymphocytes PD-L1 Immune-related genes Neoadjuvant treatment Bevacizumab